<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; White River Capital Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/white-river-capital-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ANDS) Anadys Pharmaceuticals Drug Meets Key Study Goals</title>
		<link>http://www.stockbloghub.com/2009/12/18/ands-anadys-pharmaceuticals-drug-meets-key-study-goals/23216</link>
		<comments>http://www.stockbloghub.com/2009/12/18/ands-anadys-pharmaceuticals-drug-meets-key-study-goals/23216#comments</comments>
		<pubDate>Fri, 18 Dec 2009 23:40:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Anadys Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANDS]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[RVR]]></category>
		<category><![CDATA[SOC]]></category>
		<category><![CDATA[Stoneleigh Partners Acquisition Corporation]]></category>
		<category><![CDATA[White River Capital Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23216</guid>
		<description><![CDATA[Anadys Pharmaceuticals Inc. (ANDS) announced that its lead candidate, ANA598, which is being developed for treating patients with hepatitis C virus (HCV) infections has met its key goals in a mid-stage study. The study saw HCV patients being treated with ANA598 in combination with pegylated interferon and ribavirin &#8211; the current standard of care (SOC) &#8211; at a 200 mg bid dosage level and analyzed at four weeks. The drug was generally well tolerated. No discontinuations because of serious adverse events were reported even though eight patients, seven mild and one moderate, developed rash in the interim analysis. The interim data from the four-week analysis revealed that 56% patients who received the HCV drug in combination with the SOC showed undetectable traces of the virus, Rapid Virological Response (RVR), at ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/18/ands-anadys-pharmaceuticals-drug-meets-key-study-goals/23216/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

